T1	Participants 72 185	140 patients with a threatening premature birth at the greater than or equal to 24-less than 37 week of gestation
T2	Participants 258 316	77% in the hexoprenalin and in 74% in the salbutamol group
T3	Participants 383 407	66% in both study groups
T4	Participants 598 715	11% of the mothers in the hexoprenalin group had side-effects during infusion compared to 30% in the salbutamol group
